Instead, the company is hoping to use its CD40L inhibitor drug to do a better job at inhibiting an immune response seen in transplant patients with rejection. Having said that, if it ends up being ...

Dapirolizumab pegol was better than a placebo at controlling disease activity in systemic lupus erythematosus patients in a Phase 3 trial.

The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The ...

The CD40/CD40 ligand (CD40L) costimulatory system, which amplifies immune responses and can induce inflammation, is believed to have a role in skin manifestations of other autoimmune diseases ...

Sanofi has posted encouraging results with one of its mid-stage candidates for multiple sclerosis, anti-CD40L antibody frexalimab, and says it plans to move the drug into a phase 3 programme next ...

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular ...